Quality of life predicts progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib versus interferon alfa.
In a randomized phase III trial, sunitinib was associated with significantly superior progression-free survival when compared with interferon alfa as first-line therapy in patients with metastatic renal cell carcinoma. This article investigates whether baseline quality of life and demographic and clinical variables were predictive for progression-free survival.
Cella
David
D
Center on Outcomes, Research and Education, Evanston Northwestern Healthcare, Evanston, IL; Pfizer Global Research and Development, Groton, CT, La Jolla, CA, and New York; Memorial Sloan-Kettering Cancer Center, New York, NY; and Massachusetts General Hospital Cancer Center, Boston, MA.
Cappelleri
Joseph C
JC
Bushmakin
Andrew
A
Charbonneau
Claudie
C
Li
Jim Z
JZ
Kim
Sindy T
ST
Chen
Isan
I
Michaelson
M Dror
MD
Motzer
Robert J
RJ